Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2012
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchLeena V Maramattom, Parameswaran N Hari, Linda J Burns, et al.
JCI Insight|May 2, 2023
Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHDJonathan C Poe, Jiyuan Fang, Dadong Zhang, et al.
Transplantation and Cellular Therapy|December 28, 2022
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host DiseaseChenyu Lin, Rachel A DiCioccio, Tarek Haykal, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modalityTimothy S Fenske, Mei-Jie Zhang, Jeanette Carreras, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialPhilippe Armand, Arnon Nagler, Edie A Weller, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 11, 2013
Providing personalized prognostic information for adult leukemia survivorsStephanie J Lee, Barry Storer, Hailin Wang, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 4, 2012
Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant researchLeena V Maramattom, Parameswaran N Hari, Linda J Burns, et al.
JCI Insight|May 2, 2023
Single-cell landscape analysis unravels molecular programming of the human B cell compartment in chronic GVHDJonathan C Poe, Jiyuan Fang, Dadong Zhang, et al.
Transplantation and Cellular Therapy|December 28, 2022
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host DiseaseChenyu Lin, Rachel A DiCioccio, Tarek Haykal, et al.
Blood|March 11, 2025
Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaNatalie Wuliji, Salene M W Jones, Ted A Gooley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 18, 2013
Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modalityTimothy S Fenske, Mei-Jie Zhang, Jeanette Carreras, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 16, 2013
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trialPhilippe Armand, Arnon Nagler, Edie A Weller, et al.
Cancer|August 23, 2021
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 11, 2013
Providing personalized prognostic information for adult leukemia survivorsStephanie J Lee, Barry Storer, Hailin Wang, et al.
Blood|October 19, 2022
An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AMLMohamed L Sorror, Ted A Gooley, Barry E Storer, et al.
Pageof 14